These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24613905)

  • 21. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dosed docetaxel showed equivalent efficacy but improved tolerability compared with oxaliplatin in the S-1-based first-line chemotherapy regimen for metastatic or recurrent gastric adenocarcinoma.
    Guo M; Yu Y; Wang Y; Cui Y; Li Q; Feng Y; Li W; Zhuang R; Liu T
    Med Oncol; 2015 Sep; 32(9):230. PubMed ID: 26268397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial).
    Lee KW; Chung IJ; Ryu MH; Park YI; Nam BH; Oh HS; Lee KH; Han HS; Seo BG; Jo JC; Lee HR; Kim JW; Park SR; Cho SH; Kang YK;
    Gastric Cancer; 2021 Jan; 24(1):156-167. PubMed ID: 32596783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
    Koizumi W; Nakayama N; Tanabe S; Sasaki T; Higuchi K; Nishimura K; Takagi S; Azuma M; Ae T; Ishido K; Nakatani K; Naruke A; Katada C
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):407-13. PubMed ID: 21796483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
    Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
    Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.
    Shi M; Yang Z; Lu S; Liu W; Ni Z; Yao X; Hua Z; Feng R; Zheng Y; Wang Z; Sah BK; Chen M; Zhu Z; He C; Li C; Zhang J; Yan C; Yan M; Zhu Z
    BMC Cancer; 2021 Dec; 21(1):1344. PubMed ID: 34922478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
    Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
    Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).
    Koizumi W; Takiuchi H; Yamada Y; Boku N; Fuse N; Muro K; Komatsu Y; Tsuburaya A
    Ann Oncol; 2010 May; 21(5):1001-5. PubMed ID: 19875759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective study of adjuvant albumin-bound paclitaxel plus S-1 after D2 gastrectomy versus oxaliplatin plus S-1 in gastric cancer.
    Li N; Wu H; Xu X; Wei Q; Ding Y; Liu S; Wu J; Zheng Y; Xu N; Gao Y; Jiang H
    Sci Rep; 2024 Jul; 14(1):15150. PubMed ID: 38956232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination.
    Shigeyasu K; Kagawa S; Uno F; Nishizaki M; Kishimoto H; Gochi A; Kimura T; Takahata T; Nonaka Y; Ninomiya M; Fujiwara T
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):937-43. PubMed ID: 23355040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.
    Nishina T; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Mitome T; Kageyama H; Hyodo I
    Gastric Cancer; 2019 Jan; 22(1):138-146. PubMed ID: 29948386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
    Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer.
    Zhang ZD; Kong Y; Yang W; Zhang B; Zhang YL; Ma EM; Liu HX; Chen XB; Hua YW
    World J Surg Oncol; 2014 Apr; 12():115. PubMed ID: 24758484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart review.
    Winther SB; Zubcevic K; Qvortrup C; Vestermark LW; Jensen HA; Krogh M; Sorbye H; Pfeiffer P;
    Acta Oncol; 2016 Jul; 55(7):881-5. PubMed ID: 27181284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Conversion Surgery Following S-1 plus Cisplatin or Oxaliplatin Chemotherapy for Unresectable Gastric Cancer.
    Fukuchi M; Mochiki E; Ishiguro T; Ogura T; Sobajima J; Kumagai Y; Ishibashi K; Ishida H
    Anticancer Res; 2017 Mar; 37(3):1343-1347. PubMed ID: 28314301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer.
    Iwase H; Shimada M; Tsuzuki T; Ina K; Sugihara M; Haruta J; Shinoda M; Kumada T; Goto H
    Oncology; 2011; 80(1-2):76-83. PubMed ID: 21659786
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.
    Saeki H; Emi Y; Oki E; Tokunaga S; Kakeji Y; Akagi Y; Baba H; Baba E; Maehara Y;
    BMC Cancer; 2018 Jan; 18(1):57. PubMed ID: 29310611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Lee J; Shin SJ; Chung IJ; Kim TW; Chun HG; Shin DB; Kim YH; Song HS; Han SW; Kim JG; Kim SY; Choi YJ; Chung HC
    Invest New Drugs; 2014 Jun; 32(3):561-8. PubMed ID: 24573743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
    Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH
    Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.